Innoviva (INVA) Net Income towards Common Stockholders (2010 - 2026)
Innoviva (INVA) posted Net Income towards Common Stockholders of $186.6 million for Q1 2026, up 1191.71% on a QoQ basis from -$17.1 million in Q4 2025, and up 500.51% year-over-year from $31.1 million in Q1 2025.
Innoviva (INVA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Innoviva's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $186.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 500.51% year-over-year to $186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340.2 million (up 463.02% YoY) and the FY2025 annual result came in at $326.9 million, up 1297.32% from the prior year.
- Net Income towards Common Stockholders was $186.6 million for Q1 2026 at Innoviva, up from -$17.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $282.2 million in Q3 2022 and bottomed at -$175.8 million in Q4 2023.
- A 5-year average of $32.0 million and a median of $3.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders slumped 2809.77% — and 2025, when it soared 3359.15%.
- Innoviva's Net Income towards Common Stockholders stood at -$15.9 million in 2022, then sank by 1005.62% to -$175.8 million in 2023, then surged by 91.16% to -$15.5 million in 2024, then fell by 9.99% to -$17.1 million in 2025, then soared by 1191.71% to $186.6 million in 2026.
- Business Quant data shows INVA's Net Income towards Common Stockholders at $186.6 million in Q1 2026, -$17.1 million in Q4 2025, and $107.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Innoviva | 1.59 Bn | 983.20 Mn | 75.83 Mn | 186.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.60 Mn |
| Dec 31, 2025 | -17.09 Mn |
| Sep 30, 2025 | 107.03 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.59 Mn |
| Dec 31, 2024 | -15.54 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | -34.69 Mn |
| Mar 31, 2024 | 36.52 Mn |
| Dec 31, 2023 | -175.83 Mn |
| Sep 30, 2023 | 118.19 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 34.87 Mn |
| Dec 31, 2022 | -15.90 Mn |
| Sep 30, 2022 | 282.24 Mn |
| Jun 30, 2022 | 939,000.00 |
| Mar 31, 2022 | 15.77 Mn |
| Dec 31, 2021 | -44.88 Mn |
| Sep 30, 2021 | 255.51 Mn |
| Jun 30, 2021 | 88.95 Mn |